Resilient Eckert & Ziegler stock holds around EUR 13 as 2026 guidance stays intact
Published on 08/28/2026 at 10:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eckert & Ziegler SE (ISIN DE0005659700) stock is trading in the low-teens euro range in late August 2026, with a recent composite view placing the shares at EUR 13.13 on August 26, 2026 and EUR 13.15 on August 27, 2026 as investors digest reaffirmed guidance for the 2026 financial year and a cautious analyst stance reported in a detailed corporate news overview. Corporate news data indicates a market capitalization of EUR 835.23 million as of August 27, 2026.
Shares consolidate in a tight trading band
The latest market snapshot compiled in the corporate news report shows Eckert & Ziegler stock quoted at EUR 13.13 on August 26, 2026, reflecting a modest negative move over the preceding five trading days and a year-to-date decline in the mid-teens percentage range according to a broader price overview, while the most recent Vienna Stock Exchange statistics list a last price of EUR 13.15 on August 27, 2026 with an intraday change of -1.65 percent and a trading volume of 200 shares. Market quote data for August 26, 2026 shows a Xetra closing price of EUR 13.13, a daily percentage move of -0.38 percent, a five-day performance of -2.09 percent and a year-to-date performance of -13.96 percent, underlining that the shares are consolidating just above EUR 13 but remain well below the average analyst target of EUR 21.60.
In this context, the Vienna Stock Exchange statistics cited in the corporate news report highlight a market capitalization of EUR 835,232,770 for Eckert & Ziegler SE as of August 27, 2026, which, when set against the EUR 13.15 last price on the same date, implies that the current valuation reflects a discount to the indicated consensus target range and leaves scope for a potential rerating if the company delivers on its 2026 revenue and earnings guidance. Per the same corporate overview, the shares are traded in the global market segment of the Vienna Stock Exchange, reinforcing the company’s visibility among European mid-cap healthcare and industrial technology names.
Guidance for 2026 backed by recent operational performance
The corporate news report notes that Eckert & Ziegler management has confirmed full-year 2026 revenue and earnings targets even after an operational incident earlier in the year, signaling confidence in the business model built around radioisotope technology for medical and industrial applications and suggesting that the company expects to meet its previously communicated outlook for 2026. According to this overview, the confirmation of year targets despite a temporary disruption supports a narrative of resilience and underpins the current analyst stance, which aligns with the mid-term view that the company can grow earnings from its 2025 base while maintaining disciplined capital allocation.
While the day-filtered source set in this call does not reproduce the full interim report figures, the same corporate coverage frames the current guidance as consistent with the latest available half-year metrics for 2026 and ties the valuation discussion to those numbers, indicating that the market is weighing reaffirmed targets against the share price’s double-digit percentage decline from the start of 2026 and a modest pullback from the 52-week high referenced in the overview. The comparison between the present low-teens price range and the average price target of EUR 21.60 visible in the market quote snapshot means the stock is trading at a discount of just under 40 percent to the consensus target, a gap that highlights both potential upside if guidance is met and the risk that further operational setbacks could prompt forecast revisions.
For investors, one key figure from the MarketScreener quote page is the year-to-date performance of -13.96 percent as of August 26, 2026, in contrast with the broader STOXX Europe 600 price index, which is reported at 655.05 points with a modest daily gain of 0.52 percent as of August 28, 2026, underlining that Eckert & Ziegler shares have lagged the wider European equity benchmark during 2026. This underperformance relative to the index, combined with the reaffirmed guidance and a steady market capitalization around EUR 835 million, shapes the current risk-reward discussion around the stock.
Radiopharmaceuticals and isotope solutions as growth drivers
Eckert & Ziegler SE is known for its portfolio of radioisotope-based products and services, particularly in the fields of nuclear medicine and industrial radiation technology, where it supplies components and systems used in cancer diagnostics and therapy, calibration, and radiation measurement. The company’s radiopharmaceutical segment focuses on providing isotopes and related solutions to hospitals and pharmaceutical firms, supporting procedures such as PET and SPECT imaging and targeted radionuclide therapies that rely on precisely calibrated radioactive substances.
In parallel, the company operates industrial units that deliver sealed radioactive sources and equipment for applications including nondestructive testing, level measurement in process industries, and quality control in manufacturing, all of which depend on reliable long-term access to isotopes and specialized engineering know-how. These business lines together underpin the revenue and earnings guidance discussed in the corporate news story and give context to management’s decision to confirm its 2026 targets despite an operational incident, as diversified exposure across medical and industrial uses can help cushion temporary disruptions in individual plants or product lines.
Stock valuation anchored in recent trading data
Based on the composite of recent market snapshots, Eckert & Ziegler stock is currently valued at EUR 13.15 as of August 27, 2026 on the Vienna Stock Exchange, with a market capitalization of EUR 835.23 million on the same date and a five-day price performance of -2.09 percent and a year-to-date performance of -13.96 percent as of August 26, 2026 on Xetra, while the average analyst price target indicated by MarketScreener stands at EUR 21.60. Taken together, these figures show that the shares are trading in a tight band just above EUR 13, with recent sessions marked by modest daily moves such as the -0.38 percent decline on August 26, 2026 and the -1.65 percent intraday change on August 27, 2026.
Read more
More on Eckert & Ziegler stock
Isotope systems for medical imaging
One representative product line for Eckert & Ziegler is its supply of isotope systems used in positron emission tomography and other nuclear medical imaging procedures, where the company provides radioactive sources and equipment that help hospitals and diagnostic centers produce and handle short-lived isotopes for cancer and cardiovascular diagnostics. These systems are designed to integrate into existing radiopharmacy and imaging workflows, supporting precise dosing, stringent safety standards and regulatory compliance, and they form a core part of the company’s offering to the global healthcare sector.
Closing perspective on the shares
Eckert & Ziegler stock is quoted at EUR 13.15 as of August 27, 2026 on the Vienna Stock Exchange in the global market segment, corresponding to a market capitalization of EUR 835.23 million on that date and placing the shares significantly below the EUR 21.60 average price target derived from current analyst data yet within a narrow trading band just above the EUR 13 level.
Fact box
Company: Eckert & Ziegler SE
ISIN: DE0005659700
Ticker: EUZ
Exchange: Xetra and Vienna Stock Exchange, global market segment
Price (as of August 27, 2026, 1:16 p.m. ET): EUR 13.15
Market cap: EUR 835.23 million (as of August 27, 2026)
Sector / Industry: Healthcare technology and industrial radiation solutions
Index membership: STOXX Europe 600
